Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Song KR, Chapagain RH, Tamrakar D, Shrestha R, Kanodia P, Chaudhary S, Wartel TA, Yang JS, Kim DR, Lee J, Park EL, Cho H, Lee J, Thaisrivichai P, Vemula S, Kim BM, Gupta B, Saluja T, Pansuriya RK, Ganapathy R, Baik YO, Lee YJ, Jeon S, Park Y, Her HL, Park Y, Lynch JA. Song KR, et al. Among authors: saluja t. Lancet Glob Health. 2024 May;12(5):e826-e837. doi: 10.1016/S2214-109X(24)00059-7. Lancet Glob Health. 2024. PMID: 38614631 Free PMC article. Clinical Trial.
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G, Saluja T, Chaudhary S, Tamrakar D, Kanodia P, Giri BR, Shrestha R, Uranw S, Kim DR, Yang JS, Park IY, Kyung SE, Vemula S, Reddy E J, Kim B, Gupta BP, Jo SK, Ryu JH, Park HK, Shin JH, Lee Y, Kim H, Kim JH, Mojares ZR, Wartel TA, Sahastrabuddhe S. Kumar Rai G, et al. Among authors: saluja t. Lancet Infect Dis. 2022 Apr;22(4):529-540. doi: 10.1016/S1473-3099(21)00455-2. Epub 2021 Dec 20. Lancet Infect Dis. 2022. PMID: 34942090 Free PMC article. Clinical Trial.
A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
Chaudhary S, Shah GS, Bhatta NK, Poudel P, Rai B, Uranw S, Tripathi PM, Khanal B, Ghimire A, Rai N, Gupta BP, Vemula S, Wartel TA, Sahastrabuddhe S, Saluja T. Chaudhary S, et al. Among authors: saluja t. Hum Vaccin Immunother. 2023 Dec 31;19(1):2203634. doi: 10.1080/21645515.2023.2203634. Hum Vaccin Immunother. 2023. PMID: 37128723 Free PMC article. Clinical Trial.
Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V, Raj S, Dhingra MS, Aloysia D'Cor N, Singh AP, Saluja T, Kim DR, Midde VJ, Kim Y, Vemula S, Narla SK, Sah B, Ali M. Raghava Mohan V, et al. Among authors: saluja t. PLoS One. 2019 Jun 18;14(6):e0218033. doi: 10.1371/journal.pone.0218033. eCollection 2019. PLoS One. 2019. PMID: 31211792 Free PMC article. Clinical Trial.
Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal.
Saluja T, Giri BR, Chaudhary S, Tamrakar D, Kanodia P, Palkar S, Vemula S, Chinaworapong S, Kim B, Gupta BP, Kyoung Jo S, Aspinall S, Rai GK, Steele D, Kim JH, Wartel TA, Sahastrabuddhe S. Saluja T, et al. Hum Vaccin Immunother. 2021 Jul 3;17(7):2149-2157. doi: 10.1080/21645515.2020.1855955. Epub 2021 Feb 1. Hum Vaccin Immunother. 2021. PMID: 33524278 Free PMC article.
Oral Cholera Vaccine Efficacy and Effectiveness.
Song KR, Lim JK, Park SE, Saluja T, Cho SI, Wartel TA, Lynch J. Song KR, et al. Among authors: saluja t. Vaccines (Basel). 2021 Dec 15;9(12):1482. doi: 10.3390/vaccines9121482. Vaccines (Basel). 2021. PMID: 34960228 Free PMC article. Review.
Factors affecting willingness to participate in vaccine clinical trials in an underdeveloped country: perspective from Nepal.
Chapagain RH, Adhikari S, Giri BR, Ray P, Shrestha NJ, Prajapati B, Joshi P, Pokharel S, Tamang SM, Gupta BP, Wartel TA, Sahastrabuddhe S, Rai GK, Saluja T. Chapagain RH, et al. Among authors: saluja t. Hum Vaccin Immunother. 2022 Nov 30;18(5):2051413. doi: 10.1080/21645515.2022.2051413. Epub 2022 Mar 30. Hum Vaccin Immunother. 2022. PMID: 35353657 Free PMC article.
Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
Saluja T, Rai GK, Chaudhary S, Kanodia P, Giri BR, Kim DR, Yang JS, Park IY, Kyung SE, Vemula S, Reddy E J, Kim B, Gupta BP, Jo SK, Ryu JH, Park HK, Shin JH, Lee Y, Kim H, Kim JH, Mojares ZR, Wartel TA, Sahastrabuddhe S. Saluja T, et al. Vaccine. 2022 Sep 22;40(40):5828-5834. doi: 10.1016/j.vaccine.2022.08.034. Epub 2022 Sep 3. Vaccine. 2022. PMID: 36064672 Clinical Trial.
Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal.
Chapagain RH, Maharjan J, Adhikari S, Thapa P, Kunwar K, Giri BR, Shrestha NJ, Shrestha AK, Shrestha SK, Tamang SM, Cho H, Park EL, Lee J, Lee J, Kim DR, Yang JS, Saluja T, Wartel A, Lynch J, Song KR. Chapagain RH, et al. Among authors: saluja t. Hum Vaccin Immunother. 2023 Aug 1;19(2):2239680. doi: 10.1080/21645515.2023.2239680. Hum Vaccin Immunother. 2023. PMID: 37539816 Free PMC article. Review.
Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.
Tamrakar D, Poudel P, Thapa P, Singh S, Khadgi A, Thapa S, Tamrakar R, Shrestha A, Madhup S, Rai GK, Gupta BP, Saluja T, Sahastrabuddhe S, Shrestha R. Tamrakar D, et al. Among authors: saluja t. Hum Vaccin Immunother. 2024 Dec 31;20(1):2301631. doi: 10.1080/21645515.2023.2301631. Epub 2024 Jan 8. Hum Vaccin Immunother. 2024. PMID: 38189360 Free PMC article. Clinical Trial.
91 results